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Objectives.We sought to test the hypothesis that suppression of
chemosensitivity (respiratory response to arterial blood gases)
with dihydrocodeine may improve dyspnea and exercise tolerance
in patients with chronic heart failure.
Background. Exertional dyspnea is a common limiting symp-
tom in patients with chronic heart failure. The mechanisms
underlying this symptom are not fully understood but may be
related to increased ventilation caused, in part, by the augmenta-
tion of chemosensitivity. Suppression of chemosensitivity with
mild opiates may thus improve this symptom as well as exercise
tolerance.
Methods. Twelve men with chronic heart failure (mean [6 SE]
age 65.5 6 1.5 years, range 58 to 75; left ventricular ejection
fraction 21.3 6 3.0%, range 8 to 39) received placebo or dihy-
drocodeine (1 mg/kg body weight) on two separate days in a
randomized, double-blind design. One hour later, hypoxic and
hypercapnic chemosensitivities were assessed using the transient
inhalations of pure nitrogen and the rebreathing of 7% carbon
dioxide in 93% oxygen, followed by treadmill cardiopulmonary
exercise testing. The symptoms of dyspnea and fatigue during the
exercise test were assessed using a modified Borg scale from 0 to
10.
Results. There was a significant fall in hypoxic and hypercapnic
chemosensitivities with dihydrocodeine administration compared
with placebo (0.4476 0.096 vs. 0.7466 0.104 liter/min per percent
arterial oxygen saturation, p 5 0.005; 2.480 6 0.234 vs. 2.966 6
0.283 liter/min per mm Hg, p 5 0.01, respectively). Exercise
duration was prolonged from 455 6 27 s on placebo to 512 6 27 s
(p 5 0.001) with dihydrocodeine, and peak oxygen consumption
increased from 18.06 0.6 to 19.76 0.6 ml/kg per min (p5 0.002).
The ventilatory response to exercise, characterized by the regres-
sion slope relating minute ventilation to carbon dioxide output,
decreased from 34.19 6 2.35 to 30.85 6 1.91 (p 5 0.01). With
dihydrocodeine administration, the change in the modified Borg
score for dyspnea was 20.80 (p 5 0.003) at 6 min and 20.33 (p 5
0.52) at peak exercise, whereas that for fatigue did not change
significantly. Arterial oxygen saturation was maintained during
exercise despite dihydrocodeine administration (99.3% at rest vs.
98.9% at peak exercise, p 5 0.21).
Conclusions. Augmented chemosensitivity is important in the
pathophysiology of chronic heart failure. Its suppression with
dihydrocodeine was associated with a reduction of exercise venti-
lation, an improvement in exercise tolerance and a decrease in
breathlessness. Pharmacologic modulation of chemosensitivity
may benefit patients with chronic heart failure and merits further
investigation.
(J Am Coll Cardiol 1997;29:147–52)
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Chronic heart failure causes profound physiologic alterations
in the body, including changes in neurohormonal, skeletal
muscle and respiratory function. Although the survival of
patients with chronic heart failure has been improved with
neurohormonal blocking agents such as angiotensin-converting
enzyme inhibitors (1–4) and beta-blockers (5), the symptoms
remain debilitating. Patients are often limited by exertional
dyspnea. The origin of dyspnea is multifactorial (6,7), but the
increased ventilation seen during exercise in these patients
may play a role (8). Other than increased exercise ventilation,
patients with chronic heart failure also have an abnormal
breathing pattern such that at a given minute ventilation,
respiratory rate is increased while the changes in tidal volume
are less significant compared with normal subjects (9,10). The
onset of dyspnea during exercise may indeed be related to the
disproportionate increase in respiratory rate relative to tidal
volume during exercise (9). We have recently demonstrated
that the respiratory response to arterial blood gases, or che-
mosensitivity, in patients with chronic heart failure is aug-
mented and correlated significantly with the ventilatory re-
sponse to exercise (11). This suggests that upregulated arterial
chemoreceptors may play a role in mediating the increased
exercise ventilation in these patients and contribute, in part, to
their symptoms.
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Opiate drugs have a respiratory depressant effect and are
used to relieve breathlessness—morphine being used in the
treatment of acute pulmonary edema and dihydrocodeine in
the palliation of breathlessness in chronic obstructive pulmo-
nary disease (12) and malignancies (13). Accordingly, dihydro-
codeine has also been shown to increase the exercise tolerance
of patients with chronic obstructive pulmonary disease (12).
Respiratory depression may be due to the reduced responsive-
ness of chemoreceptors to arterial blood gases, as was demon-
strated with the short-term administration of morphine (14).
Thus far, the effects of opiates on the exertional dyspnea and
exercise tolerance in patients with chronic heart failure have
not been studied. We have therefore assessed the effects of
dihydrocodeine on chemosensitivity and the exercise tolerance
in these patients, on the premise that the pharmacologic
suppression of an augmented chemosensitivity may confirm its
pathophysiologic importance in chronic heart failure and that
it may also produce symptomatic improvement, just as neuro-
hormonal blocking agents benefit patients with chronic heart
failure.
Methods
Patient characteristics and intervention. Twelve men with
stable chronic heart failure of New York Heart Association
functional class II and III were studied (15). The mean (6SE)
age was 65.5 6 1.5 years (range 58 to 75), and all patients had
a multigated acquisition radionuclide left ventricular ejection
fraction ,40% (mean 21.3 6 3.0%, range 8% to 39%). The
etiology of chronic heart failure is shown in Table 1. All
patients were taking diuretics and angiotensin-converting en-
zyme inhibitors and were nonedematous. None of them had
chest pain or inducible ischemia during previous exercise
testing or a history of pulmonary disease. Hypoxic and hyper-
capnic chemosensitivities were assessed in these patients 1 h
after the patients received placebo or dihydrocodeine (1 mg/kg
body weight) in a randomized, double-blind design on two
separate days, followed by treadmill exercise testing on each
occasion. The placebo and dihydrocodeine were given in the
form of a drink made up to 200 ml with bitter lemon, prepared
by the Department of Pharmacy, Royal Brompton Hospital.
The study was approved by the local ethics committee and all
patients gave written informed consent.
Hypoxic chemosensitivity assessment. Hypoxic chemosen-
sitivity was assessed using the transient hypoxic ventilatory
response method (11,16). This method was chosen for practical
and safety reasons because patients were not subjected to
prolonged episodes of hypoxia. Briefly, after a period of quiet
breathing in room air, the patients were given transient
inhalations of pure nitrogen, without being aware of the timing
of these inhalations, for two to eight breaths. This was repeated
10 times to provide a wide range of arterial oxygen saturations
from 75% to 100%, with appropriate intervals of air breathing
between exposures to allow arterial oxygen saturation and
end-tidal carbon dioxide concentration to return to baseline.
The maximal minute ventilation after each period of nitrogen
inhalation was obtained by averaging the largest two consecu-
tive breaths using breath by breath analysis with a heated
pneumotachograph (Amis 2000, Innovision, Odense, Den-
mark), calibrated before each test. Continuous monitoring of
oxygen and carbon dioxide was done at the mouth by respira-
tory mass spectrometry (Amis 2000, Innovision, Odense, Den-
mark), also calibrated before each test. Arterial oxygen satu-
ration was measured using a pulse oximeter (model N-200E,
Nellcor) set at the fast mode with a response time of 2 to 3 s
and a lightweight probe clipped gently on the patient’s right
earlobe. Minute ventilation was plotted against the lowest
arterial oxygen saturation reached for each period of nitrogen
inhalation. The hypoxic chemosensitivity was obtained as the
slope of the regression line relating minute ventilation to
arterial oxygen saturation and expressed in terms of liters per
minute per percent oxygen saturation (liter/min per %SaO2).
Hypercapnic chemosensitivity assessment. Hypercapnic
chemosensitivity was assessed using the rebreathing of 7%
carbon dioxide in 93% oxygen through a 6-liter bag for 4 min
(11,17). The test was stopped sooner if patients were too
breathless to continue or if end-tidal carbon dioxide concen-
tration exceeded 10%. As before, minute ventilation was
measured breath by breath using a heated pneumotachograph,
and continuous monitoring of oxygen and carbon dioxide was
done at the mouth by respiratory mass spectrometry. Hyper-
capnic chemosensitivity was obtained as the slope of the
regression line relating minute ventilation to end-tidal carbon
dioxide concentration and expressed in terms of liters per
minute per millimeters of mercury (liters/min per mm Hg).
Table 1. Clinical Characteristics of 12 Male Patients With Chronic
Heart Failure
Age (yr) 65.5 6 1.5
Height (cm) 172.9 6 1.8
Weight (kg) 77.4 6 3.1
Spirometry
FEV1 (liters) 2.78 6 0.18
FEV1 (% predicted) 90.5 6 4.9
FVC (liters) 3.48 6 0.22
FVC (% predicted) 89.9 6 4.4
FEV1/FVC (%) 80.6 6 3.2
Etiology of CHF
IHD 8
DCM 4
Symptoms (NYHA)
II 6
III 6
MUGA left ventricular ejection fraction (%) 21.36 3.0
Treatment
Diuretics 12
ACE inhibitors 12
Data are expressed as mean value 6 SE or number of patients. ACE 5
angiotensin-converting enzyme; CHF 5 congestive heart failure; DCM 5
idiopathic dilated cardiomyopathy; FEV1 5 forced expiratory volume in 1 s;
FVC 5 forced vital capacity; IHD 5 ischemic heart disease; MUGA 5
multigated acquisition radionuclide ventriculography; NYHA 5 New York
Heart Association functional class.
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Cardiopulmonary exercise testing. Cardiopulmonary exer-
cise testing was performed using a modified Bruce protocol
(18), beginning with “stage 0” at 1.0 mph and 5% gradient.
Respiratory gas exchange analysis (oxygen consumption, car-
bon dioxide output and minute ventilation) was carried out
breath by breath by means of respiratory mass spectrometry
and a heated pneumotachograph using the same system as
previously described, calibrated before each exercise testing
(19). Heart rate, assessed electrocardiographically, and blood
pressure, measured manually using a mercury sphygmoma-
nometer, were recorded before exercise, at the end of each
3-min exercise stage and at peak exercise. Arterial oxygen
saturation was measured using a pulse oximeter (Model
N-200E, Nellcor) with a probe placed on the right supraorbital
artery. At the end of each exercise stage and at peak exercise,
the patient was also asked to score the level of dyspnea and
fatigue using a modified Borg scale (20). The scale rates the
level of perceived symptoms from 0 (none) to 10 (maximum).
Patients were also asked the major symptom that stopped them
from continuing after each exercise test.
Statistical analysis. Statistical analysis was performed us-
ing the paired Student t test or repeated measures analysis of
variance and Scheffe’s F multiple comparisons test, as appro-
priate. A value p, 0.05 was considered significant. The results
are expressed as mean value 6 SE.
Results
All patients completed the study. One patient felt nause-
ated after dihydrocodeine, but this manifested after he com-
pleted the exercise testing.
Chemosensitivity and cardiopulmonary exercise testing.
Table 2 shows the significant reduction in hypoxic and hyper-
capnic chemosensitivities after the administration of dihydro-
codeine. This reduction amounted to 40% for the hypoxic
chemosensitivity and 16% for hypercapnic chemosensitivity
when compared with placebo. The results of the cardiopulmo-
nary exercise tests are also shown in Table 2. Peak oxygen
consumption increased from 18.0 ml/kg per min to 19.7 ml/kg
per min after dihydrocodeine (p 5 0.002), which was associ-
ated with a significant improvement in exercise time. Oxygen
consumption at equivalent stages during submaximal exercise,
however, did not vary significantly between placebo and dihy-
drocodeine (before exercise [placebo vs. dihydrocodeine]: 5.2
vs. 3.5 ml/kg per min, p5 0.13; at 3 min: 10.5 vs. 11.4 ml/kg per
min, p 5 0.41; at 6 min: 13.9 vs. 14.4 ml/kg per min, p 5 0.41).
The ventilatory response to exercise, characterized by the slope
of the regression line relating minute ventilation to carbon
dioxide output during exercise, was reduced by ;10% with
dihydrocodeine compared with placebo. The respiratory ex-
change ratio (R) at peak exercise was increased with dihydro-
codeine, but this was not statistically significant. The predom-
inant limiting symptom at peak exercise on placebo was
dyspnea in 10 patients and fatigue in 2. Of these 10 patients,
the major limiting symptom at peak exercise with dihydroco-
deine remained dyspnea for eight and fatigue for two.
Exercise heart rate, blood pressure and arterial oxygen
saturation. Table 3 shows the hemodynamic data, end-tidal
carbon dioxide concentration and arterial oxygen saturation at
rest, at 3 min of exercise, at 6 min of exercise and at peak
exercise. There was no difference in heart rate or blood
pressure with dihydrocodeine administration versus placebo.
End-tidal carbon dioxide concentration was significantly
higher with dihydrocodeine than with placebo at peak exercise.
There was a nonsignificant fall in arterial oxygen saturation at
peak exercise when comparing dihydrocodeine with placebo.
Focusing on the end-tidal carbon dioxide concentration when
patients received placebo, there was a trend toward a decrease
at peak exercise compared with the rest value. In contrast, when
patients received dihydrocodeine, there was a trend toward an
increase in the end-tidal carbon dioxide concentration during
exercise. A nonsignificant fall in arterial oxygen saturation during
exercise was also seen, compared with the rest value.
Exercise ventilation and Borg score. Figure 1 compares the
minute ventilation, respiratory rate and tidal volume during
exercise with dihydrocodeine and placebo. There was a signif-
icant reduction in minute ventilation during submaximal exer-
cise with dihydrocodeine, which was accounted for principally
by the reduction in respiratory rate. The minute ventilation at
peak exercise was similar with both treatments, bearing in
mind that patients receiving dihydrocodeine exercised for a
longer time. Table 4 shows the modified Borg score for
Table 2. Chemosensitivity and Cardiopulmonary Exercise Test Results of Patients After Placebo and
Dihydrocodeine Administration
Placebo Dihydrocodeine
p
Value
Hypoxic chemosensitivity (liter/min per % SaO2) 0.746 6 0.104 0.447 6 0.096 0.005
Hypercapnic chemosensitivity (liter/min per mm Hg) 2.9666 0.283 2.480 6 0.234 0.01
Peak oxygen consumption (ml/kg per min) 18.06 0.6 19.7 6 0.6 0.002
V˙E–V˙CO2 slope 34.19 6 2.35 30.85 6 1.91 0.011
Exercise duration (s) 455 6 27 512 6 27 0.001
Respiratory exchange ratio (R) 1.26 1.31 0.17
Data are expressed as mean value 6 SE, unless otherwise indicated. V˙E–V˙CO2 slope 5 slope of regression line
relating minute ventilation and carbon dioxide output during exercise and is taken as an index of the ventilatory response
to exercise; % SaO2 5 percent arterial oxygen saturation.
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dyspnea and for fatigue. It demonstrates a reduction in breath-
lessness at submaximal exercise with the administration of
dihydrocodeine, but, in contrast, there was no significant
change in the perception of fatigue.
Discussion
We have shown that dihydrocodeine reduced breathless-
ness, at least during submaximal exercise, and also improved
exercise tolerance. There are several possible ways that dihy-
drocodeine may do this.
Chemosensitivity and dyspnea. The first and most likely
way that dihydrocodeine reduced breathlessness and improved
exercise tolerance is through a reduction of chemosensitivity.
The mean hypoxic and hypercapnic chemosensitivities of the
chronic heart failure patients who participated in this study
while receiving placebo were significantly higher than the
normal control values in our laboratory (0.293 6 0.056 liter/
min per %SaO2 and 2.02 6 0.24 liter/min per mm Hg,
respectively) (11). We have demonstrated that the augmented
chemosensitivity was reduced with dihydrocodeine administra-
tion. There was a concomitant reduction in minute ventilation
at all stages, except at peak exercise, accounted for mainly by
a decrease in respiratory rate. As pointed out earlier, the
genesis of dyspnea may, in part, be due to an excessive increase
in exercise ventilation as well as the disproportionate rise in
respiratory rate relative to tidal volume (10). A higher respi-
ratory rate may conceivably cause respiratory muscle fatigue,
contributing to the sensation of dyspnea (21). In addition, such
a characteristic mode of ventilation is inefficient because the
proporation of dead space (hence wasted) ventilation in in-
creased (8,9). That minute ventilation was similar at peak
exercise with placebo and dihydrocodeine administration also
lends credence to the notion that the predominant mechanism
by which dihydrocodeine causes respiratory depression is through
a reduction of chemoreceptor-mediated respiratory drive rather
than by the generalized depression of the central nervous system.
Of relevance is the recent finding that there is an associa-
tion between blunted hypoxic chemosensitivity and the lack of
perception of dyspnea in asthmatic patients with a history of a
near-fatal status asthmaticus (22). Other studies have shown a
reduction in the perception of dyspnea in asthmatic patients
who had both carotid bodies removed as part of the treatment
Figure 1. Comparison of minute ventilation, respiratory rate and tidal
volume during exercise with placebo (open symbols) and dihydroco-
deine (solid symbol) administration. *p , 0.05 (using repeated-
measures analysis of variance).
Table 3. Pulse, Systolic Blood Pressure, End-Tidal Carbon Dioxide
Concentration and Arterial Oxygen Saturation at Rest, at 3 Minutes
of Exercise, at 6 Minutes of Exercise and at Peak Exercise With
Placebo and Dihydrocodeine
Placebo Dihydrocodeine p Value
Before exercise
Pulse (min21) 73 6 2 72 6 2 0.43
Systolic blood pressure (mm Hg) 1186 7 116 6 5 0.70
End-tidal CO2 concentration (%) 4.95 6 0.17 5.01 6 0.15 0.73
Arterial O2 saturation (%) 100 6 0 99.3 6 0.3 0.03
At 3 min
Pulse (min21) 94 6 5 95 6 5 0.74
Systolic blood pressure (mm Hg) 1296 9 128 6 7 0.64
End-tidal CO2 concentration (%) 5.05 6 0.15 5.20 6 0.18 0.36
Arterial O2 saturation (%) 99.8 6 0.11 99.4 6 0.26 0.18
At 6 min
Pulse (min21) 113 6 5 110 6 4 0.19
Systolic blood pressure (mm Hg) 1346 7 140 6 8 0.80
End-tidal CO2 concentration (%) 4.95 6 0.27 5.32 6 0.25 0.50
Arterial O2 saturation (%) 99.5 6 0.26 98.9 6 0.40 0.09
At peak exercise
Pulse (min21) 132 6 6 132 6 5 0.90
Systolic blood pressure (mm Hg) 1446 10 140 6 9 0.32
End-tidal CO2 concentration (%) 4.66 6 0.22 5.12 6 0.24 0.008
Arterial O2 saturation (%) 99.4 6 0.26 98.9 6 0.40 0.08
Data are expressed as mean value 6 SE.
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of asthma, suggesting a close association between hypoxic
chemosensitivity and the perception of this symptom (23,24). It
may be that afferent signals from chemoreceptors not only act
on the medullary respiratory centers, but are also directly
perceived as breathlessness. Although a greater reduction in
hypoxic chemosensitivity with dihydrocodeine administration
vis-a`-vis hypercapnic chemosensitivity (40% vs. 16%) was
noted, our study does not provide further information on the
specific contribution of each toward the generation of dyspnea.
Despite a reduction in chemosensitivity after dihydrocodeine
administration, the major limiting symptom at peak exercise
did not change in the majority of patients, probably because the
patients exercised for a longer time and reached a similar level of
minute ventilation at peak exercise, compared with placebo.
Alteration in hemodynamic data and sympathetic drive.
The second possible way that dihydrocodeine improved exer-
cise tolerance may be through the beneficial hemodynamic
effects of dihydrocodeine. Morphine has been shown to have
both venodilatory (25) and systemic arteriolar dilatory effects
(26) secondary to a reduction in sympathetic activity. This
reduction may again be partly due to the suppression of
chemoreceptors, as they have an excitatory action on the brain
stem and can increase sympathetic outflow (27,28). Indeed,
increased sympathetic outflow caused by an augmented che-
moreflex is thought to contribute to the neurohormonal ab-
normality in chronic heart failure (28). However, previous
studies have shown that improving hemodynamic data with
vasodilator drugs in patients with chronic heart failure did not
necessarily improve exercise tolerance or symptoms in the
short term (29). The hemodynamic effects of dihydrocodeine
are also probably less than those of morphine considering that
it is less potent (30). Although we did not measure the central
venous pressure or the systemic vascular resistance in these
patients, there were no evident changes in blood pressure or
heart rate to suggest a significant alteration in hemodynamic
effects or sympathetic drive. Thus, it is less likely that dihydro-
codeine improved exercise tolerance by altering hemodynamic
data or sympathetic activity.
Alteration in central perception. The third possible way
that dihydrocodeine reduced breathlessness and improved
exercise tolerance is through the alteration of central percep-
tion of discomfort, both of dyspnea and fatigue. However, it is
unlikely that this is the main explanation because there was an
absence of significant improvement in the perceived symptom
of fatigue with dihydrocodeine, as would be expected if there
was a general alteration in central perception.
Maintenance of arterial oxygen saturation. As expected
with the reduction in chemosensitivity, there was a significant
increase in end-tidal carbon dioxide concentration at peak
exercise with dihydrocodeine compared with placebo. In con-
trast, the fall in arterial oxygen saturation at peak exercise with
dihydrocodeine administration was not significant compared
with the pre-exercise value. This suggests that oxygen saturation
was satisfactorily maintained during exercise, despite dihydroco-
deine administration, and did not cause significant hypoxia.
Increased peak oxygen consumption. We were surprised to
see that there was an improvement in peak oxygen consump-
tion after dihydrocodeine administration. The most likely
reason for this is that with the reduction in the perceived
sensation of breathlessness, these patients were able to im-
prove their exercise duration. Because of the delayed oxygen
kinetics in patients with chronic heart failure (31), the peak
oxygen consumption may not reflect maximal oxygen consump-
tion, and the slow upward drift with exercise prolongation may
account for the improvement in peak exercise consumption
with dihydrocodeine. As discussed earlier, it is unlikely that
there was a significant alteration in hemodynamic data or
sympathetic drive with dihydrocodeine to affect cardiac work.
It is also pertinent to note that oxygen consumption at rest
and during submaximal exercise with dihydrocodeine adminis-
tration was not significantly different from that with placebo.
This is in agreement with a previous report with codeine
administration (32), although in contrast to another with
morphine (33). It is probably due to the lesser potency of
dihydrocodeine in comparison to morphine. It is thought that
morphine may reduce the metabolic rate for, as yet, unknown
physiologic reasons (33). The observation in our study that
oxygen consumption during submaximal exercise with dihydro-
codeine was similar to that with placebo goes against the
reduction of metabolic rate as a factor in causing increased
exercise tolerance, as has been suggested in studies of chronic
obstructive pulmonary disease (12).
Study limitations. All patients in this study were men. This
was not a deliberate study design; patient recruitment was
random and voluntary. It is, however, very unlikely that the
general findings of the study would be altered if there were
female patients in our study. Chemosensitivity is also not
known to be affected by gender (35).
Table 4. Modified Borg Scores for Dyspnea and for Fatigue During Exercise Testing With Placebo
and Dihydrocodeine
Modified Borg Score (Dyspnea)
(scale 0–10)
Modified Borg Score (Fatigue)
(scale 0–10)
Placebo Dihydrocodeine p Value Placebo Dihydrocodeine p Value
At 3 min 1.176 0.35 1.33 6 0.28 0.64 1.336 0.36 1.33 6 0.33 1.0
At 6 min 3.606 0.22 2.91 6 0.25 0.003 3.006 0.49 2.64 6 0.37 0.21
Peak exercise 5.676 0.74 5.33 6 0.67 0.52 5.716 0.54 5.67 6 0.48 0.91
Data are expressed as mean value 6 SE.
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Our study was designed to demonstrate the contribution of
chemosensitivity to increased exercise ventilation and breath-
lessness in chronic heart failure due to left ventricular systolic
dysfunction. We therefore did not recruit patients with mitral
stenosis in our study. Furthermore, patients with mitral steno-
sis have much restrictive lung disease (more so than chronic
heart failure patients), and minute ventilation may underesti-
mate the true output of the respiratory center (36,37). The
interpretation of data in these patients may be difficult and is
confounded by other pulmonary factors.
Conclusions. This study has several implications. Dihydro-
codeine appears to be beneficial in the short term under
exercise laboratory conditions. This is likely to be related to the
suppression of the augmented chemosensitivity seen in pa-
tients with chronic heart failure. The potential benefits of
longer term administration of dihydrocodeine in chronic heart
failure patients who are limited by breathlessness despite
optimal conventional therapy merit further investigation. This,
however, has to be considered against the background of
possible drug tolerance and the small risk of dependence.
Other pharmacologic means of chemoreceptor modulation
(such as oxygen therapy [34]) are also likely to produce
symptomatic benefit, just as neurohormonal blocking agents
benefit patients with chronic heart failure, and they also merit
further research. Second, this study demonstrates that aug-
mented chemosensitivity contributes to the abnormal respira-
tory function of patients with chronic heart failure and has
pathophysiologic significance. Finally, the chemoreflex is not
only important in influencing the increased exercise ventilation
and the perception of breathlessness in chronic heart failure,
but may also contribute to the neurohormonal abnormality by
increasing sympathetic outflow through its excitatory action on
the brain stem, as discussed (27,28).
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